Tenax Therapeutics, Inc. (TENX) stock
TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.62+0.01 (+0.62%)
Close on Nov 13, 2026Market cap $60.63MP/E –Yield –
Tenax Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Tenax Therapeutics's ebitda for the twelve months ending Dec 31, 2024 was -$19.49M. For fiscal 2024 it was -$19.49M. The highest annual figure on record is $11.06M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$19.49M | – |
| FY2023 | Dec 31, 2023 | -$8.23M | -174.4% |
| FY2022 | Dec 31, 2022 | $11.06M | – |
| FY2021 | Dec 31, 2021 | -$32.72M | -431.5% |
| FY2020 | Dec 31, 2020 | $9.87M | – |
| FY2019 | Dec 31, 2019 | -$8.55M | – |
| FY2018 | Dec 31, 2018 | -$6.88M | – |
| FY2017 | Dec 31, 2017 | -$9.19M | – |
| FY2015 | Apr 30, 2015 | -$14.67M | – |
| FY2014 | Apr 30, 2014 | -$16.46M | – |
| FY2013 | Apr 30, 2013 | -$5.04M | – |
| FY2012 | Apr 30, 2012 | -$8.01M | -173.7% |
| FY2011 | Apr 30, 2011 | $10.87M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$7.30M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$4.62M | -318.0% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$3.67M | -396.7% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$3.91M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$13.12M | -613.4% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $2.12M | -27.4% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $1.24M | -56.8% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$1.54M | -156.6% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $2.56M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $2.92M | -23.3% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $2.86M | +45.7% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $2.72M | -88.5% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$62.24M | -2296.1% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $3.80M | +70.9% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $1.97M | -8.4% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $23.75M | +790.7% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $2.83M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $2.23M | -1.6% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $2.15M | +17.8% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $2.67M | +60.4% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$14.30M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $2.26M | +45.3% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $1.82M | -3.7% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $1.66M | +35.7% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$11.56M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $1.56M | +18.5% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $1.89M | -37.3% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $1.23M | -65.0% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -$17.03M | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $1.31M | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $3.02M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $3.50M | – |
| Q4 FY2015CQ1 2015 | Apr 30, 2015 | -$5.09M | – |
See a number that looks wrong?